[Clinical and experimental study on its regulatory function of yi xin decoction (heart-nourishing decoction) to lipids metabolic disturbance in coronary heart disease].
In this research, 74 patients with coronary heart disease (CHD) were grouped in matched-pair, one group took orally Inositol and Mai Tong as the control group, the other group took orally Yi Xin Decoction as the tested group. Indices, i. e. serum levels of apolipoprotein A-1 (Apo A-1), apolipoprotein B (Apo-B), high density lipoprotein cholesterol (HDL-c), high density lipoprotein subcomponent cholesterol (HDL2-c), B-lipoprotein (B-LP), total cholesterol (Tch), triglyceride (TG) were measured before and after treatment for 28 days; the results showed that the patients with CHD have prominent derangement of lipid metabolism, which is similar to previous reports. Yi Xin Decoction modified according to Syndrome Differentiation, produced the effect of decreasing the serum Apo-B levels and TG. It also increased Apo-A-1, HDL-c and HDL2-c respectively. Moreover the effect of lowering Apo-B and raising HDL-c in the Yi Xin Decoction group was better than that in the control group. There was no side effect at all; all these indicated that Yi Xin Decoction has a remarkable function of regulating the disturbance of lipid metabolism in CHD patients. In order to further investigate the curative effect of Yi Xin Decoction and elucidate its mechanism, the authors have also investigated Yi Xin Decoction on the experimental mice with hyperlipemia. The result Showed that Tch and TG in atromid and Yi Xin Decoction group reduced after medication, P < 0.01. In comparing with control group, the HDL-c and acidic cholesterol in stool Yi Xin Decoction group rose, P < 0.05. The above study has provided reliable basis for the clinical application of Yi Xin Decoction and also a new medicine to regulate disturbance of lipid metabolism for CHD patients.
Liang
H
H
Dept. of Int. Med. Affiliated Hospital of Heilong-Jiang College of TCM, Harbin.
Wang
X
X
D000818:Animals; D001054:Apolipoproteins A / Q000032:analysis; D001055:Apolipoproteins B / Q000097:blood; D016022:Case-Control Studies; D008076:Cholesterol, HDL / Q000097:blood; D003327:Coronary Disease / Q000097:blood / Q000188:drug therapy*; D004365:Drugs, Chinese Herbal / Q000627:therapeutic use*; D005260:Female; D006801:Humans; D050356:Lipid Metabolism; D008297:Male; D008875:Middle Aged; D051381:Rats; D017207:Rats, Sprague-Dawley; D014280:Triglycerides / Q000097:blood
D001054:Apolipoproteins A; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D004365:Drugs, Chinese Herbal; D014280:Triglycerides